Why did FDA approve pirtobrutinib for untreated CLL/SLL without 17p deletion?

The FDA cleared pirtobrutinib for untreated chronic lymphocytic leukemia/small lymphocytic lymphoma in patients without 17p deletion, according to a September 30, 2026 update cited by AJMC. The bigger issue now is sequencing: how payers, pathway committees, and oncologists will position it in front-line care and manage access.